Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

mAbs

Volumn 1, Issue 5, 2009, Pages 481-490

  Sutherland, May Kung ^a   Yu, Changpu ^a   Lewis, Timothy S ^a   Miyamoto, Jamie B ^a   Morris Tilden, Carol A ^a   Jonas, Mechthild ^a   Sutherland, Jennifer ^a   Nesterova, Albina ^a   Gerber, Hans Peter ^a,b   Sievers, Eric L ^a   Grewal, Iqbal S ^a   Law, Che Leung ^a  

^a SEATTLE GENETICS INC   (United States)

^b PFIZER INC   (United States)

Author keywords

CD33; Cytokine; Effector function; Immunotherapy; Monoclonal antibody; Myeloid malignancies; Signaling

Indexed keywords

ANTILEUKEMIC AGENT; CHEMOKINE; CYTOKINE; GEMTUZUMAB OZOGAMICIN; GROWTH FACTOR; LINTUZUMAB; MULTIDRUG RESISTANCE PROTEIN 1; SGN 33; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD33 ANTIGEN; DIFFERENTIATION ANTIGEN; HUM195 ANTIBODY; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; SCID MOUSE; TUMOR VOLUME; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL STRAIN HL 60; CELL STRAIN U937; DISEASE MODEL; IMMUNOLOGY; METABOLISM; MORTALITY; MOUSE MUTANT; PATHOLOGY; PHAGOCYTOSIS; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; PHAGOCYTOSIS; TREATMENT OUTCOME; U937 CELLS;

EID: 77950352683     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.5.9288     Document Type: Article

References (60)

1. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481-3485
2. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K, Dohner H. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006; 108:3280-3288 (Pubitemid 44776864)
3. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341:1051-1062
4. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323-3329 (Pubitemid 27229818)
5. Drach J, Zhao S, Drach D, Korbling M, Engel H, Andreeff M. Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis. Leuk Lymphoma 1995; 16:419-424
6. Gekeler V, Beck J, Noller A, Wilisch A, Frese G, Neumann M, et al. Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann Hematol 1994; 69:19-24. (Pubitemid 24255445)
7. Malayeri R, Filipits M, Suchomel RW, Zochbauer S, Lechner K, Pirker R. Multidrug resistance in leukemias and its reversal. Leuk Lymphoma 1996; 23:451-458 (Pubitemid 27029655)
8. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78:586-592
9. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67:1048-1053 (Pubitemid 16116418)
10. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002; 118:560-566 (Pubitemid 44698513)
11. Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 1989; 3:339-348 (Pubitemid 19127556)
12. Fenton C, Perry CM. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs 2005; 65:2405-2427 (Pubitemid 41573610)
13. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 2007; 21:66-71. (Pubitemid 44921836)
14. Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002; 16:813-819 (Pubitemid 34537552)
15. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000; 14:1436-1443 (Pubitemid 30601355)
16. Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene 2007; 26:3679-3690 (Pubitemid 46842699)
17. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109:4168-4170
18. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52:6761-6767 (Pubitemid 23006275)
19. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 1998; 4:1421-1428 (Pubitemid 28265224)
20. Caron PC, Lai LT, Scheinberg DA. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res 1995; 1:63-70.
21. Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003; 17:314-318 (Pubitemid 36266906)
22. Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson J, Wood BL, et al. Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33. Blood 2007; 110:159.
23. Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJL, Wood B, et al. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 experience. Leukemia Lymphoma 2009.
24. Xu Y, Scheinberg DA. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model. Clin Cancer Res 1995; 1:1179-1187
25. Guc D, Canpinar H, Kucukaksu C, Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur J Haematol 2000; 64:3-9. (Pubitemid 30055538)
26. Balaian L, Zhong RK, Ball ED. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol 2003; 31:363-371
27. Paul SP, Taylor LS, Stansbury EK, McVicar DW. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000; 96:483-490
28. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem 1999; 274:11505-11512 (Pubitemid 129518395)
29. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol 1999; 29:3440-3449 (Pubitemid 29527791)
30. Bruserud O, Ryningen A, Olsnes AM, Stordrange L, Oyan AM, Kalland KH, Gjertsen BT. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007; 92:332-341 (Pubitemid 350143542)
31. Hsu HC, Lee YM, Tsai WH, Jiang ML, Ho CH, Ho CK, Wang SY. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 2002; 63:64-69 (Pubitemid 34977939)
32. Lowenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993; 81:281-292 (Pubitemid 23027141)
33. Yan L, Anderson GM, DeWitte M, Nakada MT. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 2006; 42:793-802.
34. McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007; 109:1185-1192 (Pubitemid 46220667)
35. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-1669 (Pubitemid 38821999)
36. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, et al. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 1992; 79:2229-2236
37. Stiff PJ, Schulz WC, Bishop M, Marks L. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia. Blood 1991; 77:355-362
38. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40:109-123 (Pubitemid 36959821)
39. Hara T, Kojima A, Fukuda H, Masaoka T, Fukumori Y, Matsumoto M, Seya T. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br J Haematol 1992; 82:368-373
40. Lajaunias F, Dayer JM, Chizzolini C. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol 2005; 35:243-251 (Pubitemid 40123871)
41. Legdeur MC, Broekhoven MG, Schuurhuis GJ, Beelen RH, Ossenkoppele GJ. Monocyte-chemoattractant-protein-1-mediated migration of human monocytes towards blasts from patients with acute myeloid leukemia. Cancer Immunol Immunother 2001; 50:16-22.
42. Mazur G, Wrobel T, Butrym A, Kapelko-Slowik K, Poreba R, Kuliczkowski K. Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia. Neoplasma 2007; 54:285-289
43. Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R. Overexpression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 2005; 75:485-491 (Pubitemid 41687782)
44. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104:788-793 (Pubitemid 41113679)
45. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4:540-550
46. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003; 5:31-36 (Pubitemid 36553576)
47. Uesato N, Fukui K, Maruhashi J, Tojo A, Tajima N. JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model. Exp Hematol 2006; 34:1385-1392 (Pubitemid 44374834)
48. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004; 10:2253-2264 (Pubitemid 38445682)
49. Kossman SE, Scheinberg DA, Jurcic JG, Jimenez J, Caron PC. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Clin Cancer Res 1999; 5:2748-2755 (Pubitemid 29493948)
50. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174:817-826 (Pubitemid 40094277)
51. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-758 (Pubitemid 34525533)
52. Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 2005; 105:289-291 (Pubitemid 40053095)
53. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13:47-58. (Pubitemid 34119634)
54. McCormack E, Bruserud O, Gjertsen BT. Review: genetic models of acute myeloid leukaemia. Oncogene 2008; 27:3765-3779 (Pubitemid 351862057)
55. Brinkman-Van der Linden EC, Angata T, Reynolds SA, Powell LD, Hedrick SM, Varki A. CD33/Siglec-3 binding specificity, expression pattern and consequences of gene deletion in mice. Mol Cell Biol 2003; 23:4199-4206 (Pubitemid 36666423)
56. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25:1315-1321 (Pubitemid 350076512)
57. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106:4086-4092 (Pubitemid 41775913)
58. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006; 107:1166-1173 (Pubitemid 43156319)
59. Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992; 148:1149-1154
60. Nelson EJ, Zinkin NT, Hinkle PM. Fluorescence methods to assess multidrug resistance in individual cells. Cancer Chemother Pharmacol 1998; 42:292-299